Nebivolol Krka (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors, which reduces heart rate and myocardial contractility. At the same time, it stimulates endothelial β3 receptors, leading to increased nitric‑oxide production and vasodilation. This dual action lowers peripheral resistance and blood pressure while supporting better blood flow.

The appropriate dose of Nebivolol Krka is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Dosage may be started low and titrated upward, but exact numbers should only be provided by a qualified prescriber.

Safety data for Nebivolol during pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Nebivolol Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nebivolol is distinguished by its high β1‑selectivity and its ability to promote nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects and better tolerability compared with non‑selective beta blockers. It may be preferred in patients where additional vasodilatory effects are beneficial, though individual response varies.

Nebivolol tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and extreme heat to maintain stability throughout its shelf life.

Nebivolol is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare cases of hepatic dysfunction or allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, difficulty breathing, or signs of liver injury.

Nebivolol should be avoided in individuals with known hypersensitivity to the drug, severe bradycardia, advanced atrioventricular block without a pacemaker, decompensated heart failure, or uncontrolled asthma. It is also contraindicated in patients taking certain strong CYP2D6 inhibitors unless a prescriber decides otherwise.